Crohn's & Colitis Foundation Visiting IBD Fellowship 2021-2022

Professional Education Resources & Reading List 2021

Professional Reading list

Professional Reading List 2021

(updated 5/2020)

Section: Practice Guidelines

Lichtenstein, Gary R, Edward V Loftus, Kim L Isaacs, Miguel D Regueiro, Lauren B Gerson, and Bruce E Sands. **"ACG Clinical Guideline: Management of Crohn's Disease in Adults."** *American Journal of Gastroenterology* 113, no. 4 (2018): 481-517. http://dx.doi.org/10.1038/ajg.2018.27.

- ACG Guideline on Crohn's Disease managaement, 2018

Feuerstein, J. D., K. L. Isaacs, Y. Schneider, S. M. Siddique, Y. Falck-Ytter, and S. Singh. **"AGA Clinical Practice Guidelines on the Management of Moderate to Severe Ulcerative Colitis."** *Gastroenterology* 158, no. 5 (Apr 2020): 1450-61. http://dx.doi.org/10.1053/j.gastro.2020.01.006.

- AGA Guideline on management of moderate-severe UC, 2020

Ko, C. W., S. Singh, J. D. Feuerstein, C. Falck-Ytter, Y. Falck-Ytter, and R. K. Cross. **"AGA Clinical Practice Guidelines on the Management of Mild-to-Moderate Ulcerative Colitis."** *Gastroenterology* 156, no. 3 (Feb 2019): 748-64. http://dx.doi.org/10.1053/j.gastro.2018.12.009.

- AGA Guideline on management of mild-moderate UC, 2019

Rubin, David T., Ashwin N. Ananthakrishnan, Corey A. Siegel, Bryan G. Sauer, and Millie D. Long. **"ACG Clinical Guideline: Ulcerative Colitis in Adults."** *American Journal of Gastroenterology* 114, no. 3 (2019): 384-413. http://dx.doi.org/10.14309/ajg.0000000000000152.

- ACG Guideline on management of UC, 2019

Section: Treatment Strategies (Combination therapy, treatment targets, drug monitoring and de-escalation

Colombel, Jean Frédéric, William J. Sandborn, Walter Reinisch, Gerassimos J. Mantzaris, Asher Kornbluth, Daniel Rachmilewitz, et al. **"Infliximab, Azathioprine, or Combination Therapy for Crohn's Disease."** *New England Journal of Medicine* 362, no. 15 (2010): 1383-95. http://dx.doi.org/10.1056/NEJMoa0904492.

- SONIC Study – landmark trial comparing mono vs. combotherapy in Crohn's disease

Panaccione, R., S. Ghosh, S. Middleton, J. R. Márquez, B. B. Scott, L. Flint, et al. **"Combination Therapy with Infliximab and Azathioprine Is Superior to Monotherapy with Either Agent in Ulcerative Colitis."** *Gastroenterology* 146, no. 2 (Feb 2014): 392-400.e3. http://dx.doi.org/10.1053/j.gastro.2013.10.052.

- UC-SUCCESS Study – similar trial comparing mono vs. combotherapy in UC

Colombel, J. F., R. Panaccione, P. Bossuyt, M. Lukas, F. Baert, T. Vaňásek, et al. **"Effect of Tight Control Management on Crohn's Disease (Calm): A Multicentre, Randomised, Controlled Phase 3 Trial."** *Lancet* 390, no. 10114 (Dec 23 2018): 2779-89. http://dx.doi.org/10.1016/s0140-6736(17)32641-7.

- CALM Study – major randomized trial studying treat to target approach ("tight control") in Crohn's disease

Peyrin-Biroulet, L., W. Sandborn, B. E. Sands, W. Reinisch, W. Bemelman, R. V. Bryant, et al. **"Selecting Therapeutic Targets in Inflammatory Bowel Disease (Stride): Determining Therapeutic Goals for Treat-to-Target."** *Am J Gastroenterol* 110, no. 9 (Sep 2015): 1324-38. http://dx.doi.org/10.1038/ajg.2015.233.

- STRIDE – consensus statement by IOIBD providing guidance on treatment targets in IBD

Bouguen, G., B. G. Levesque, B. G. Feagan, A. Kavanaugh, L. Peyrin-Biroulet, J. F. Colombel, et al. **"Treat to Target: A Proposed New Paradigm for the Management of Crohn's Disease."** *Clin Gastroenterol Hepatol* 13, no. 6 (Jun 2015): 1042-50.e2. http://dx.doi.org/10.1016/j.cgh.2013.09.006.
- Review article discussing treat to target approach

Adedokun, O. J., W. J. Sandborn, B. G. Feagan, P. Rutgeerts, Z. Xu, C. W. Marano, et al. **"Association between Serum Concentration of Infliximab and Efficacy in Adult Patients with Ulcerative Colitis."** *Gastroenterology* 147, no. 6 (Dec 2014): 1296-307.e5. http://dx.doi.org/10.1053/j.gastro.2014.08.035.
- Post-hoc analysis of ACT1 & ACT2 demonstrating utility of measuring drug levels

Feuerstein, J. D., G. C. Nguyen, S. S. Kupfer, Y. Falck-Ytter, and S. Singh. **"American Gastroenterological Association Institute Guideline on Therapeutic Drug Monitoring in Inflammatory Bowel Disease."** *Gastroenterology* 153, no. 3 (Sep 2017): 827-34. http://dx.doi.org/10.1053/j.gastro.2017.07.032.
- Recent AGA Guideline on therapeutic drug monitoring

Sands, Bruce E., Laurent Peyrin-Biroulet, Edward V. Loftus, Silvio Danese, Jean-Frédéric Colombel, Murat Törüner, et al. **"Vedolizumab Versus Adalimumab for Moderate-to-Severe Ulcerative Colitis."** *New England Journal of Medicine* 381, no. 13 (2019): 1215-26. http://dx.doi.org/10.1056/NEJMoa1905725.
- VARSITY Study – landmark randomized trial comparing Vedolizumab to Adalimumb in UC (first randomized head to head biologic trial in IBD).

Hirten, R. P., P. L. Lakatos, J. Halfvarson, and J. F. Colombel. **"A User's Guide to De-Escalating Immunomodulator and Biologic Therapy in Inflammatory Bowel Disease."** *Clin Gastroenterol Hepatol* 18, no. 6 (May 2020): 1336-45. http://dx.doi.org/10.1016/j.cgh.2019.12.019.
- Review article on de-escalation of therapy

Reenaers, C., J. Y. Mary, M. Nachury, Y. Bouhnik, D. Laharie, M. Allez, et al. **"Outcomes 7 Years after Infliximab Withdrawal for Patients with Crohn's Disease in Sustained Remission."** *Clin Gastroenterol Hepatol* 16, no. 2 (Feb 2018): 234- 43.e2. http://dx.doi.org/10.1016/j.cgh.2017.09.061.
- STORI Study – long term outcomes of a large cohort of patients followed after de-escalation of infliximab

Section: Emerging Therapies

Weisshof, R., K. El Jurdi, N. Zmeter, and D. T. Rubin. **"Emerging Therapies for Inflammatory Bowel Disease."** *Adv Ther* 35, no. 11 (Nov 2018): 1746-62. http://dx.doi.org/10.1007/s12325-018-0795-9.
- Review article summarizing many current pipeline therapies for IBD.

Selected topics: Postoperative Crohn's

Nguyen, Geoffrey C., Edward V. Loftus, Jr., Ikuo Hirano, Yngve Falck–Ytter, Siddharth Singh, Shahnaz Sultan, et al. **"American Gastroenterological Association Institute Guideline on the Management of Crohn's Disease after Surgical Resection."** *Gastroenterology* 152, no. 1 (2017): 271-75. Accessed 2020/04/13. http://dx.doi.org/10.1053/j.gastro.2016.10.038.
- AGA Guideline on post-operative management in Crohn's disease

Regueiro, M., B. G. Feagan, B. Zou, J. Johanns, M. A. Blank, M. Chevrier, et al. **"Infliximab Reduces Endoscopic, but Not Clinical, Recurrence of Crohn's Disease after Ileocolonic Resection."** *Gastroenterology* 150, no. 7 (Jun 2016): 1568-78. http://dx.doi.org/10.1053/j.gastro.2016.02.072.

- PREVENT Study: large, well known randomized study evaluating infliximab in post-operative Crohn's disease

De Cruz, P., M. A. Kamm, A. L. Hamilton, K. J. Ritchie, E. O. Krejany, A. Gorelik, et al. **"Crohn's Disease Management after Intestinal Resection: A Randomised Trial."** *Lancet* 385, no. 9976 (Apr 11 2015): 1406-17. http://dx.doi.org/10.1016/s0140-6736(14)61908-5.

- POCER Study: well known study supporting the role of "active care" after surgery in Crohn's disease (i.e., 6 month post-operative colonoscopy).

Selected topics: Epidemiology

Ng, S. C., H. Y. Shi, N. Hamidi, F. E. Underwood, W. Tang, E. I. Benchimol, et al. **"Worldwide Incidence and Prevalence of Inflammatory Bowel Disease in the 21st Century: A Systematic Review of Population-Based Studies."** *Lancet* 390, no. 10114 (Dec 23 2018): 2769-78. http://dx.doi.org/10.1016/s0140-6736(17)32448-0.

- Systemic review of the epidemiology of IBD globally

Park, K. T., O. G. Ehrlich, J. I. Allen, P. Meadows, E. M. Szigethy, K. Henrichsen, et al. **"The Cost of Inflammatory Bowel Disease: An Initiative from the Crohn's & Colitis Foundation."** *Inflamm Bowel Dis* 26, no. 1 (Jan 1 2020): 1-10. http://dx.doi.org/10.1093/ibd/izz104.

- Study evaluating the costs of care for patients with IBD utilizing a large commercial research database

Section: Microbiome

David, L. A., C. F. Maurice, R. N. Carmody, D. B. Gootenberg, J. E. Button, B. E. Wolfe, et al. **"Diet Rapidly and Reproducibly Alters the Human Gut Microbiome."** *Nature* 505, no. 7484 (Jan 23 2014): 559-63. http://dx.doi.org/10.1038/nature12820.

- Nature review discussing microbiome shifts

Gevers, D., S. Kugathasan, L. A. Denson, Y. Vázquez-Baeza, W. Van Treuren, B. Ren, E. Schwager, et al. **"The Treatment- Naive Microbiome in New-Onset Crohn's Disease."** *Cell Host Microbe* 15, no. 3 (Mar 12 2014): 382-92. http://dx.doi.org/10.1016/j.chom.2014.02.005.

- Article discussing microbiome profiles in patients with Crohn's disease

Selected topics: Health Maintenance

Farraye, F. A., G. Y. Melmed, G. R. Lichtenstein, and S. V. Kane. **"ACG Clinical Guideline: Preventive Care in Inflammatory Bowel Disease."** *Am J Gastroenterol* 112, no. 2 (Feb 2017): 241-58. http://dx.doi.org/10.1038/ajg.2016.537.

Caldera, Freddy, Francis A. Farraye, and Sunanda Kane. **"The Who and Why of Herpes Zoster Vaccination in Patients with Inflammatory Bowel Diseases."** *Clinical Gastroenterology and Hepatology* 16, no. 12 (2018): 1872-75. Accessed 2020/04/13. http://dx.doi.org/10.1016/j.cgh.2018.08.061.

Section: Colorectal Cancer in IBD

Shah, S. C. and S. H. Itzkowitz. **"Reappraising Risk Factors for Inflammatory Bowel Disease-Associated Neoplasia: Implications for Colonoscopic Surveillance in IBD."** *J Crohns Colitis* (Mar 9 2020). http://dx.doi.org/10.1093/ecco-jcc/jjaa040.

- Review article of risk factors for colorectal cancer in IBD

Feuerstein, J. D., S. Rakowsky, L. Sattler, A. Yadav, J. Foromera, L. Grossberg, and A. S. Cheifetz. **"Meta-Analysis of Dye- Based Chromoendoscopy Compared with Standard- and High-Definition White-Light Endoscopy in Patients with Inflammatory Bowel Disease at Increased Risk of Colon Cancer."** *Gastrointest Endosc* 90, no. 2 (Aug 2019): 186- 95.e1. http://dx.doi.org/10.1016/j.gie.2019.04.219.

- Meta-analysis of chromoendoscopy vs. white light colonoscopy in IBD

Laine, L., T. Kaltenbach, A. Barkun, K. R. McQuaid, V. Subramanian, and R. Soetikno. **"Scenic International Consensus Statement on Surveillance and Management of Dysplasia in Inflammatory Bowel Disease."** *Gastroenterology* 148, no. 3 (Mar 2015): 639-51.e28. http://dx.doi.org/10.1053/j.gastro.2015.01.031.

- SCENIC statement – well known position statement advocating use of chromoendoscopy in IBD

Soetikno, R., V. Subramanian, T. Kaltenbach, R. V. Rouse, S. Sanduleanu, N. Suzuki, et al. **"The Detection of Nonpolypoid (Flat and Depressed) Colorectal Neoplasms in Patients with Inflammatory Bowel Disease."** *Gastroenterology* 144, no. 7 (Jun 2013): 1349-52, 52.e1-6. http://dx.doi.org/10.1053/j.gastro.2013.04.008.

- Article discussing pre-malignant lesions and role of chromoendoscopy on surveillance colonoscopy in IBD

Selected topics: Risks of Therapy

Lichtenstein, L., Y. Ron, S. Kivity, S. Ben-Horin, E. Israeli, G. M. Fraser, et al. **"Infliximab-Related Infusion Reactions: Systematic Review."** *J Crohns Colitis* 9, no. 9 (Sep 2015): 806-15. http://dx.doi.org/10.1093/ecco-jcc/jjv096.

- Review of infusion reactions

Beaugerie, L., J. F. Rahier, and J. Kirchgesner. **"Predicting, Preventing, and Managing Treatment-Related Complications in Patients with Inflammatory Bowel Diseases."** *Clin Gastroenterol Hepatol* 18, no. 6 (May 2020): 1324-35.e2. http://dx.doi.org/10.1016/j.cgh.2020.02.009.

- Review article on managing treatment related complications

Beaugerie, L. and J. Kirchgesner. **"Balancing Benefit Vs Risk of Immunosuppressive Therapy for Individual Patients with Inflammatory Bowel Diseases."** *Clin Gastroenterol Hepatol* 17, no. 3 (Feb 2019): 370-79. http://dx.doi.org/10.1016/j.cgh.2018.07.013.

- Review article on risk vs benefit of immunosuppressives

Selected topics: Special Populations

Ott, C. and J. Schölmerich. **"Extraintestinal Manifestations and Complications in IBD."** *Nat Rev Gastroenterol Hepatol* 10, no. 10 (Oct 2013): 585-95. http://dx.doi.org/10.1038/nrgastro.2013.117.

- Review article of extraintestinal manifestations in IBD

Mahadevan, U., C. Robinson, N. Bernasko, B. Boland, C. Chambers, M. Dubinsky, et al. **"Inflammatory Bowel Disease in Pregnancy Clinical Care Pathway: A Report from the American Gastroenterological Association Ibd Parenthood Project Working Group."** *Gastroenterology* 156, no. 5 (Apr 2019): 1508-24.

http://dx.doi.org/10.1053/j.gastro.2018.12.022.
- AGA Care pathway for management of Pregnancy in IBD

Quinn, K. P., A. L. Lightner, W. A. Faubion, and L. E. Raffals. **"A Comprehensive Approach to Pouch Disorders."** *Inflamm Bowel Dis* 25, no. 3 (Feb 21 2019): 460-71. http://dx.doi.org/10.1093/ibd/izy267.
- Review article discussing pouch disorders in patients with IBD

Shen, B. **"Pouchitis: What Every Gastroenterologist Needs to Know."** *Clin Gastroenterol Hepatol* 11, no. 12 (Dec 2013): 1538-49. http://dx.doi.org/10.1016/j.cgh.2013.03.033.
- Review article on pouchitis

Ananthakrishnan, A. N., T. Donaldson, K. Lasch, and V. Yajnik. **"Management of Inflammatory Bowel Disease in the Elderly Patient: Challenges and Opportunities."** *Inflamm Bowel Dis* 23, no. 6 (Jun 2017): 882-93. http://dx.doi.org/10.1097/mib.0000000000001099.
- Review article discussing management of IBD in the elderly

Lin, S. C., A. Goldowsky, K. Papamichael, and A. S. Cheifetz. **"The Treatment of Inflammatory Bowel Disease in Patients with a History of Malignancy."** *Inflamm Bowel Dis* 25, no. 6 (May 4 2019): 998-1005. http://dx.doi.org/10.1093/ibd/izy376.
- Review article discussing management of IBD patients with a prior malignancy

Mamtani, R., A. S. Clark, F. I. Scott, C. M. Brensinger, B. Boursi, L. Chen, et al. **"Association between Breast Cancer Recurrence and Immunosuppression in Rheumatoid Arthritis and Inflammatory Bowel Disease: A Cohort Study."** *Arthritis Rheumatol* 68, no. 10 (Oct 2016): 2403-11. http://dx.doi.org/10.1002/art.39738.
- Cross disciplinary article discussing management of IBD (and RA) patients with prior breast cancer

Singh, Siddharth, Sherman Picardo, and Cynthia H. Seow. **"Management of Inflammatory Bowel Diseases in Special Populations: Obese, Old, or Obstetric."** *Clinical Gastroenterology and Hepatology* (Nov 2019): Epub. http://dx.doi.org/10.1016/j.cgh.2019.11.009.
- Review article summarizing key management principles for common challenging scenarios in IBD

Optional Readings & References

Treatment – Mesalamines, Thiopurines, and Steroids

Lim, W. C., Y. Wang, J. K. MacDonald, and S. Hanauer. **"Aminosalicylates for Induction of Remission or Response in Crohn's Disease."** *Cochrane Database of Systematic Reviews*, no. 7 (2016). https://dx.doi.org/10.1002/14651858.CD008870.pub2.

- Cochrane review of 5-ASA use in Crohn's disease

Wang, Y., C. E. Parker, T. Bhanji, B. G. Feagan, and J. K. MacDonald. **"Oral 5-Aminosalicylic Acid for Induction of Remission in Ulcerative Colitis."** *Cochrane Database of Systematic Reviews*, no. 4 (2016). https://dx.doi.org/10.1002/14651858.CD000543.pub4.

- Cochrane review of 5-ASA use in UC induction

Wang, Y., C. E. Parker, B. G. Feagan, and J. K. MacDonald. **"Oral 5-Aminosalicylic Acid for Maintenance of Remission in Ulcerative Colitis."** *Cochrane Database of Systematic Reviews*, no. 5 (2016). https://dx.doi.org/10.1002/14651858.CD000544.pub4.

- Cochrane review of 5-ASA use in UC maintenance

Hanauer, S. B., W. J. Sandborn, and G. R. Lichtenstein. **"Evolving Considerations for Thiopurine Therapy for Inflammatory Bowel Diseases-a Clinical Practice Update: Commentary."** *Gastroenterology* 156, no. 1 (Jan 2019): 36-42. https://dx.doi.org/10.1053/j.gastro.2018.08.043.

- Review article on thiopruine use

Rezaie, A., M. E. Kuenzig, E. I. Benchimol, A. M. Griffiths, A. R. Otley, A. H. Steinhart, et al. **"Budesonide for Induction of Remission in Crohn's Disease."** *Cochrane Database of Systematic Reviews*, no. 6 (2015). http://dx.doi.org/10.1002/14651858.CD000296.pub4.

- Cochrane review of budesonide ("Entocort") in Crohn's disease

Travis, S. P., S. Danese, L. Kupcinskas, O. Alexeeva, G. D'Haens, P. R. Gibson, et al. **"Once-Daily Budesonide MMX in Active, Mild-to-Moderate Ulcerative Colitis: Results from the Randomised Core Ii Study."** *Gut* 63, no. 3 (Mar 2014): 433- 41. https://dx.doi.org/10.1136/gutjnl-2012-304258.

- Pivotal trial of budesonide MMX ("Uceris") for UC.

Treatment – Anti-TNF Biologics

Targan, Stephan R., Stephen B. Hanauer, Sander J.H. van Deventer, Lloyd Mayer, Daniel H. Present, Tanja Braakman, et al. **"A Short-Term Study of Chimeric Monoclonal Antibody Ca2 to Tumor Necrosis Factor A for Crohn's Disease."** *New England Journal of Medicine* 337, no. 15 (1997): 1029-36. https://dx.doi.org/10.1056/nejm199710093371502.

- Landmark induction trial of Infliximab ("CA2") for Crohn's disease

Hanauer, S. B., B. G. Feagan, G. R. Lichtenstein, L. F. Mayer, S. Schreiber, J. F. Colombel, et al. **"Maintenance Infliximab for Crohn's Disease: The Accent I Randomised Trial."** *Lancet* 359, no. 9317 (May 4 2002): 1541-9. https://dx.doi.org/10.1016/s0140-6736(02)08512-4.

- ACCENT I: Pivotal infliximab maintenance trial in Crohn's

Sands, Bruce E., Frank H. Anderson, Charles N. Bernstein, William Y. Chey, Brian G. Feagan, Richard N. Fedorak, et al. **"Infliximab Maintenance Therapy for Fistulizing Crohn's Disease."** *New England Journal of Medicine* 350, no. 9 (2004): 876-85. https://dx.doi.org/10.1056/NEJMoa030815.

- Key trial demonstrating efficacy of infliximab in fistulizing disease (only dedicated fistula healing study in IBD).

Rutgeerts, Paul, William J. Sandborn, Brian G. Feagan, Walter Reinisch, Allan Olson, Jewel Johanns, et al. **"Infliximab for Induction and Maintenance Therapy for Ulcerative Colitis."** *New England Journal of Medicine* 353, no. 23 (2005): 2462-76. https://dx.doi.org/10.1056/NEJMoa050516.

- Pivotal trial demonstrating efficacy of Infliximab in UC

Hanauer, S. B., W. J. Sandborn, P. Rutgeerts, R. N. Fedorak, M. Lukas, D. MacIntosh, et al. **"Human Anti-Tumor Necrosis Factor Monoclonal Antibody (Adalimumab) in Crohn's Disease: The Classic-I Trial."** *Gastroenterology* 130, no. 2 (Feb 2006): 323-33; quiz 591. https://dx.doi.org/10.1053/j.gastro.2005.11.030.

- CLASSIC-1: key trial of Adalimumab induction in Crohn's

Colombel, J. F., W. J. Sandborn, P. Rutgeerts, R. Enns, S. B. Hanauer, R. Panaccione, et al. **"Adalimumab for Maintenance of Clinical Response and Remission in Patients with Crohn's Disease: The Charm Trial."** *Gastroenterology* 132, no. 1 (Jan 2007): 52-65. https://dx.doi.org/10.1053/j.gastro.2006.11.041.

- CHARM Trial: Adalimumab maintenenace trial in Crohn's

Reinisch, W., W. J. Sandborn, D. W. Hommes, G. D'Haens, S. Hanauer, S. Schreiber, et al. **"Adalimumab for Induction of Clinical Remission in Moderately to Severely Active Ulcerative Colitis: Results of a Randomised Controlled Trial."** *Gut* 60, no. 6 (Jun 2011): 780-7. https://dx.doi.org/10.1136/gut.2010.221127.

- ULTRA 1: Adalimumab induction trial in UC

Sandborn, W. J., G. van Assche, W. Reinisch, J. F. Colombel, G. D'Haens, D. C. Wolf, et al. **"Adalimumab Induces and Maintains Clinical Remission in Patients with Moderate-to-Severe Ulcerative Colitis."** *Gastroenterology* 142, no. 2 (Feb 2012): 257-65.e1-3. https://dx.doi.org/10.1053/j.gastro.2011.10.032.

- ULTRA 2: Adalimumab maintenance trial in UC

Sandborn, William J., Brian G. Feagan, Simeon Stoinov, Pieter J. Honiball, Paul Rutgeerts, David Mason, et al. **"Certolizumab Pegol for the Treatment of Crohn's Disease."** *New England Journal of Medicine* 357, no. 3 (2007): 228-38. http://dx.doi.org/10.1056/NEJMoa067594.

- PRECISE 1: pivotal tial of Certolizumab as induction therapy for CD

Schreiber, Stefan, Mani Khaliq-Kareemi, Ian C. Lawrance, Ole Østergaard Thomsen, Stephen B. Hanauer, Juliet McColm, et al. **"Maintenance Therapy with Certolizumab Pegol for Crohn's Disease."** *New England Journal of Medicine* 357, no. 3 (2007): 239-50. http://dx.doi.org/10.1056/NEJMoa062897.

- PRECISE 2: pivotal trial of Certolizumab as maintenace therapy for CD

Sandborn, W. J., B. G. Feagan, C. Marano, H. Zhang, R. Strauss, J. Johanns, et al. **"Subcutaneous Golimumab Induces Clinical Response and Remission in Patients with Moderate-to-Severe Ulcerative Colitis."** *Gastroenterology* 146, no. 1 (Jan 2014): 85-95; quiz e14-5. http://dx.doi.org/10.1053/j.gastro.2013.05.048.

- PURSUIT: pivotal trial of Golimumab as induction therapy for UC

Sandborn, W. J., B. G. Feagan, C. Marano, H. Zhang, R. Strauss, J. Johanns, et al. **"Subcutaneous Golimumab Maintains Clinical Response in Patients with Moderate-to-Severe Ulcerative Colitis."** *Gastroenterology* 146, no. 1 (Jan 2014): 96-109.e1. http://dx.doi.org/10.1053/j.gastro.2013.06.010.

- PURSUIT: pivotal trial of Golimumab as maintenance therapy for UC

Treatment – Novel Biologics & Small Molecules

Sandborn, William J., Brian G. Feagan, Paul Rutgeerts, Stephen Hanauer, Jean-Frédéric Colombel, Bruce E. Sands, et al. **"Vedolizumab as Induction and Maintenance Therapy for Crohn's Disease."** *New England Journal of Medicine* 369, no. 8 (2013): 711-21. https://dx.doi.org/10.1056/NEJMoa1215739.

- GEMINI 2: pivotal trial of vedolizumab in Crohn's disease

Feagan, Brian G., Paul Rutgeerts, Bruce E. Sands, Stephen Hanauer, Jean-Frédéric Colombel, William J. Sandborn, et al. **"Vedolizumab as Induction and Maintenance Therapy for Ulcerative Colitis."** *New England Journal of Medicine* 369, no. 8 (2013): 699-710. https://dx.doi.org/10.1056/NEJMoa1215734.

- GEMINI 1: pivotal trial of Vedolizumab in UC

Feagan, Brian G., William J. Sandborn, Christopher Gasink, Douglas Jacobstein, Yinghua Lang, Joshua R. Friedman, et al. **"Ustekinumab as Induction and Maintenance Therapy for Crohn's Disease."** *New England Journal of Medicine* 375, no. 20 (2016): 1946-60. https://dx.doi.org/10.1056/NEJMoa1602773.

- UNITI Trials: pivotal trials of ustekinumab in Crohn's

Sands, Bruce E., William J. Sandborn, Remo Panaccione, Christopher D. O'Brien, Hongyan Zhang, Jewel Johanns, et al. **"Ustekinumab as Induction and Maintenance Therapy for Ulcerative Colitis."** *New England Journal of Medicine* 381, no. 13 (2019): 1201-14. https://dx.doi.org/10.1056/NEJMoa1900750.

- UNIFI Trials: key trials demonstrating ustekinumab efficacy in UC

Sandborn, William J., Chinyu Su, Bruce E. Sands, Geert R. D'Haens, Séverine Vermeire, Stefan Schreiber, et al. **"Tofacitinib as Induction and Maintenance Therapy for Ulcerative Colitis."** *New England Journal of Medicine* 376, no. 18 (2017): 1723-36. https://dx.doi.org/10.1056/NEJMoa1606910.

- OCTAVE Trials: pivotal trials of tofacitinib in UC

Miscellaneous

Regueiro, M., F. Velayos, J. B. Greer, C. Bougatsos, R. Chou, S. Sultan, and S. Singh. **"American Gastroenterological Association Institute Technical Review on the Management of Crohn's Disease after Surgical resection."** *Gastroenterology* 152, no. 1 (Jan 2017): 277-95.e3. http://dx.doi.org/10.1053/j.gastro.2016.10.039.

- Technical review accompanying the AGA post-operative Crohn's guideline

Zhu, H., X. R. Wu, E. Queener, R. P. Kiran, F. H. Remzi, and B. Shen. **"Clinical Value of Surveillance Pouchoscopy in Asymptomatic Ileal Pouch Patients with Underlying Inflammatory Bowel Disease."** *Surg Endosc* 27, no. 11 (Nov 2013): 4325-32. http://dx.doi.org/10.1007/s00464-013-3054-9.

- Study evaluating rate of dysplasia and other findings in asymptomatic patients with pouch disorders